COMPASS Pte Ltd, a Singapore-based Regulatory Technology firm, today announced the launch of its next-generation Know Your ...

The open-label, first-in-human Phase I/Ib study is evaluating CER-1236's preliminary safety and efficacy in participants.

Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. A novel ...

Denfy’s revamped AML Screening software now includes new risk categories, better PEP status labeling, and other built-in AML ...

A cross-continental study suggests that in the treatment of acute myeloid leukemia, age affects survival, independent of ...

The Cyprus Securities and Exchange Commission (CySEC) has reached a €150,000 settlement with investment firm Aquilla Nummus ...

Panelists discuss how IDH inhibitors, particularly ivosidenib combined with azacitidine, represent potentially the greatest ...

South Korea’s crypto sector is under heightened scrutiny after transfers to Cambodia jumped 1,400-fold last year, exposing ...

Detailed price information for Astellas Pharma Inc (ALPMF) from The Globe and Mail including charting and trades.

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to M2T-CD33 (LTI-214) for the treatment of ...

M2T-CD33 (LTI-214) has received FDA orphan drug designation, offering incentives like tax credits and market exclusivity for AML treatment. The treatment targets CD33, a glycoprotein present in 90% of ...

CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces the ...